Chinese biopharma BeiGene has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. 15 January 2019
Canada’s AbSci, which is focussed on biotherapeutic discovery and manufacturing technologies, today announced a collaboration with French pharma major Sanofi. 9 January 2019
Danish biotech Genmab says that it has achieved a $75 million sales volume milestone in its Darzalex (daratumumab) collaboration with Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson. 9 January 2019
UK-based T Cell Receptor (TCR) biotech firm Immunocore today announced that Bahija Jallal has been appointed as chief executive and director of the board. 7 January 2019
Japan’s Sosei Group will receive a $15 million payment from AstraZeneca after reaching a clinical development milestone with its partnered next generation immuno-oncology candidate AZD4635. 7 January 2019
US biotech Spectrum Pharmaceuticals saw its shares fall as much as 13% yesterday, despite announcing that it had submitted a Biologics License Application (BLA) with the US Food and Drug Administration for Rolontis (eflapegrastim). 28 December 2018
Astellas Pharma and Kotobuki Pharmaceutical have won approval in Japan for a new indication for Suglat (ipragliflozin L-Proline), to cover treatment of type 1 diabetes. 21 December 2018
Anticancer vaccines will be revolutionized by the use of techniques that personalize them to individual patients, according to research discussed at the ESMO Immuno-Oncology Congress in Geneva. 19 December 2018
Saint Petersburg-based BIOCAD has presented positive Phase III data from the PLANETA study of netakimab in patients with moderate to severe plaque psoriasis. 19 December 2018
Eli Lilly and Aduro Biotech have agreed a research and licensing deal for Aduro's cGAS-STING Pathway Inhibitor program, which seeks to develop novel immunotherapies for autoimmune and other inflammatory diseases. 19 December 2018
The UK’s Virion Biotherapeutics has appointed former Ablynx chief executive Edwin Moses as chairman of the board, replacing Jeffrey Almond. 17 December 2018
Staten Biotechnology and Novo Nordisk have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. 17 December 2018
Swedish biotech firm BioArctic today revealed that, along with partner AbbVie, it has received US Federal Trade Commission (FTC) clearance to license BioArctic’s alpha-synuclein antibody portfolio for Parkinson’s disease and other potential indications to AbbVie. 14 December 2018
Closely-held US biotech firm Ridgeback Biotherapeutics has entered into a patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for intellectual property related to the monoclonal antibody mAb114, an experimental treatment for Ebola. 14 December 2018
Fast-growing Chinese biotech WuXi AppTec debuted on the Hong Kong Stock Exchange on Thursday. The firm’s closing share price was roughly level with its initial public offering (IPO) price of $68 Hong Kong dollars ($9). 13 December 2018
AVEO Oncology has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of the Anglo-Swedish pharma major’s Imfinzi (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with its own Fotivda (tivozanib). 12 December 2018
Dutch drugmaker Helix Healthcare, a subsidiary of India’s Aurobindo Pharma, has entered into a joint venture with Shandong Luoxin Pharmaceutical for the manufacture of a nebuliser inhaler and other products. 12 December 2018
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024